Semin Thromb Hemost 2009; 35(2): 168-180
DOI: 10.1055/s-0029-1220325
© Thieme Medical Publishers

Whole Blood Platelet Aggregometry and Platelet Function Testing

David L. McGlasson1 , George A. Fritsma2
  • 1Wilford Hall Medical Center, United States Air Force Lackland AFB, Texas
  • 2The Fritsma Factor, Your Interactive Hemostasis Resource Clinical Associate Professor, Pathology University of Alabama at Birmingham, Birmingham, Alabama
Further Information

Publication History

Publication Date:
30 April 2009 (online)

ABSTRACT

Platelet aggregometry has been the reference method employed to detect, diagnose, and monitor qualitative platelet disorders since the early 1960s. Lumiaggregometry and impedance-based whole blood lumiaggregometry have advantages over light transmittance aggregometry in that they provide for enhanced specimen management and increase the test sensitivity to impairment of platelet granule secretion. Whole blood lumiaggregometry detects and identifies congenital and acquired platelet plasma membrane receptor defects, metabolic pathway secretion disorders, and storage pool deficiency. Whole blood lumiaggregometry is also being applied to antiplatelet therapy monitoring and identifies aspirin and thienopyridine resistance. There is growing interest in using impedance-based whole blood lumiaggregometry for near-patient whole blood platelet analysis and antiplatelet therapy monitoring. This article will also discuss other whole blood testing processes for assessing platelet function, particularly as applied to assessing the effect of antiplatelet medication.

REFERENCES

David L McGlasson, M.S. , C.L.S./N.C.A. 

59 CSPG/SGVUL 2200 Berquist Drive

Building 4430, Lackland AFB, TX 78236-9908

Email: [email protected]